Context:Carcinoma cervix is the most common genital tract carcinoma encountered among females in
I. Introduction
With 528,000 new cases every year, cervical cancer is the fourth most common cancer affecting women worldwide, after breast, colorectal and lung cancers; [1] it is also the fourth most common cause of cancer death worldwide(266,000 deaths in 2012). [1] Almost 70% of the global burden falls in underdeveloped areas and more than one-fifth of all new cases are diagnosed in India. [1, 2] The Pap test (cervical cytology) is considered the most cost effective cervical cancer screening programme ever devised. [3] Credit for its conception and development goes to George N. Papanicolaou. [4] According to American Cancer Society, ideal time to take pap smear is 5 days after menstruation. Studies also showed that cervical carcinoma is preceded by a spectrum of intraepithelial neoplastic changes which are precancerous lesions and has been termed as Cervical intraepithelial neoplasia or CIN. [5] CIN is defined as a spectrum of cellular atypia of mild degree at the base of the cervical squamous epithelium to a severe degree involving full thickness of the epithelium. [5] The original terminology of dysplasia and carcinoma in situ was replaced by CIN, proposed by Richart, in order to emphasise the continuum of the disease. [5] Now , the Bethesda system of terminologies have been introduced to subclassify the lesions into grades-Low grade and High grade Squamous intraepithelial lesions(SIL). [5] Treatment of these precancerous lesions are simple ,safe, sometimes non-destructive and usually curative. [6] Thus it is felt that an organized screening programme aimed at the high risk female population should significantly reduce the morbidity and mortality.
Further many epidemiological studies have established the role of HPV in the development of cervical cancer and its precursor lesions. [5] HPV detection increases the sensitivity of cervical cytology. [7] The gene amplification assays like PCR is the most powerful tool for the epidemiological investigation of HPV infection or cervical cancer. [7] It is now the gold standard for research. [7] On the other hand ,serological tests for HPV are not standardized or commercialized. [7] However,in most studies the concordance of serological results and HPV DNA detection was reasonably high. [8] We have thus evaluated role of HPV serology in cervical cancer screening in perimenopausal women.
II. Materials And Methods
Approval from the institutional ethics committee was taken beforehand and an informed consent from each subject included in the study was also obtained.Perimenopausal transitional years are defined as the years prior to menopause that encompass the change from normal ovulatory cycles to cessation of menses. [9] The average age of menopause is 51 years worldwide. [9] In this studyperimenopausal women (40-50) attending the out-patient department of gynaecology and obstetrics and satisfying the following inclusion and exclusion criteria were evaluated, over a one year period (February 2013-January 2014). The inclusion criteria were:  Persistent vaginal discharge  Post-coital bleeding  Intermenstrual bleeding  Post-menopausal bleeding  Dyspareunia  Or,if found to have an unhealthy cervix on per speculum examination The exclusion criteria proposed were:  Women with previous history of vaccination against HPV  Women with active vaginal bleeding  Gross tumor in cervix  Patients whose biopsy samples were not obtained Initially 135 perimenopausal women were screened by Pap smear. However those who did not consented to the procedure of cervical biopsy were excluded from the study. Ninety perimenopausal women were, thus, selected in the study by Simple Random Sampling and a cross-sectional observational study was done. An informed consent and a detailed history regarding their socio-demographic profile was taken. Materials for Pap smear was obtained with an AYRE'S SPATULA and endocervical brush from both ectocervix and endocervix and were immediately fixed in 95% ethyl alcohol fixative for 45 minutes. Four milliliters of blood was collected in a clot vial for HPV serology. Four quadrant biopsies were taken from the cervix and collected in 10% formal saline in the same sitting.
Following material collection, staining of cervical smear by Papanicolaou method was done. Detailed microscopic examination of cervical smears and evaluation using The Bethesda System,2001 was done. Any inadequate smears were repeated in the next visit.Tissue obtained from cervical punch biopsy was processed next and stained with Haematoxylin and Eosin for Histopathological interpretation.The frequency of various cytological and histological abnormalities were tabulated.An inter-rater reliability between cytology and histology, using kappa statistic, was performed through SPSS18 version.
Results for HPV serology was obtained next, with the help of DRGInternational,Inc.HPVIgG ELISA kit (DRG International Inc.,USA;EIA-4907). HPV VLP Serology was performed among all patients satisfying inclusion criteria irrespective of cytological status.The sera were stored at -20 0 C for 6 months and the ELISA was performed in two batches 6 months apart.Any haemolysed or visibly hyperlipemic samples were discarded.
III. Results
Ninety cases, in the age range of 40-50 years were sampled from among all the perimenopausal women attending the out-patient department of gynaecology and obstetrics over a period of one year.The women were of the age range of 40-50 years. The mean age group was found to be 42.32±2.96 years. Majority of the women were of the age group of 40-42 years.Cytological evaluation of cervical smears showed that most of the cases, that is 61.1% (55 out of 90 cases) were inflammatory. This is followed by LSIL, that is, 16 All the above calculations were done excluding ASCUS/ASC-H cases and patients with 'inflammatory' smears and 'within normal limit' were categorized as non-diseased population.There was moderate or intermediate degree of agreement between cytological and histological interpretation. The interrater variability for the raters(cytology vs histology) or kappa value was found to be 0.456 [ Table 2 ], which is interpreted as 'moderate agreement' between cytology and histology of cervical lesions.Only one sample was reactive for HPV IgG ELISA (89 samples were non-reactive).The reactive sample was that of a 50 year old woman with a CIN2 histological diagnosis (inflammatory smear on cytology).
IV. Discussion
Cervical cancer is preceded by a distinct latent period of more than a decade. [11] This interval between preinvasive disease (CIN) and cervical cancer provides us with the opportunity to prevent cervical cancer through screening. Most of the cases with preinvasive disease predominate in the fourth and fifth decade of life. [12] So in this present study we have chosen the fifth decade of life,that is,the perimenopausal age group, where both the rate of abnormal smears and invasive cancers are higher than in any age group. [12, 13] Tamboli et al recorded the prevalence of inflammatory smears as 50.91%, LSIL as 14.55%, HSIL as 10.9% and ASCUS as 8.64%. [14] However they reported a higher prevalence of squamous cell carcinoma (15%) than the present study(4.44%). [14] Saha et alalso reported the prevalence of ASCUS, LSIL, HSIL,SCC and Benign lesions as 2.32%,18.6%,20.9%,6.9% and 51.16% respectively. [15] When compared to the present study, the prevalence of HSIL is found to be markedly higher (8.9% in the present study). Like the present study, inflammatory smears constituted the majority of the smears.
Bal et al recorded the prevalence of ASCUS,LSIL, HSIL,SCC as 0.3%,2.7%,0.7%,1.3% respectively. [16] Majority of the smears were inflammatory (74.3%) which is similar to that of our study. [16] However, the epithelial cell abnormalities constituted only about 5% of the smears unlike 38.89% derived from our study. [16] A possible explanation may be due to screening of a high risk group like perimenopausal women in the present study as compared to the aforesaid study.
Abaliet al recorded the prevalences of CIN1, CIN2, CIN3, and SCC as 22.7, 3.7, 9 and 7.4% respectively. [17] The prevalence of the non-neoplastic group histologically was 56.9%. [17] The prevalence of CIN2 is lower and CIN3 is higher than the present study. However the net prevalence of CIN2 and CIN3 taken together is similar to the present study. The prevalence of CIN1 and the non-neoplastic group corroborated with the present study.
Katz et al recorded the prevalence of CIN 1,CIN2, CIN3, and SCC as 21%,21.3%,18% and 2.4% (including both invasive and microinvasive squamous cell carcinoma) respectively. [18] The prevalence of CIN1 in the present study is the same as above. However, the prevalence of CIN2 and CIN3 were much higher than the present study. This may be due to the larger sample size of 334 women [18] as compared to 90 women in our study. Secondly, the women in the above study underwent colposcopic directed biopsy which may also increase the sensitivity of histopathology. Also the proportion of women with squamous cell carcinoma is lower than in the present study.
The diagnostic accuracy of cytology or Pap smear in the present study (89.5%) was higher than the other studies. Nawaz FH et al in 2005 reported an accuracy of 74%. [19] Anschau et alreported as 69.8% in 2011. [20] Tamboli et al in 2014 reported accuracy of cervical cytology as 74.09%. [14] Anschauet al in 2011 showed kappa value of 0.498 when cytology and histology results were matched according to The Bethesda 2010, showing moderate degree of agreement between histology and cytology, which corroborated with the present study. [20] However, Katz et al in 2012 found the kappa value for conventional cervical cytology screening as 0.261, representing fair agreement. [18] This may be due to interpretation error or sampling error. Further there was only one reactive sample, so no association between HPV serology and cervical dysplasia/cancer could be obtained. Thus, the aim of this study to evaluate HPV serology as a screening tool was not fulfilled.
Rama et al found that the prevalence of positive serology for anti HPV antibodies in healthy young women with an abnormal cytology was only 1.75 times that of abnormal cytology and negative
Evaluation Of Pap Smear And HpvVlp Serology In Clinically Suspected Cases Of Cervical
DOI: 10.9790/0853-1603064449 www.iosrjournals.org 47 | Page serology. [21] Thus, they concluded that serological results showed no association with abnormal cytological results. [21] This observation is consistent with the present study. Achour et al detected HPV-specific antibodies in sera of 60 women, with inflammatory Pap smears, of reproductive, perimenopausal and post-menopausal age group. [22] Results showed that six patients (10%) (showed a positive reactivity to at least one of the HPV-16 or HPV-18 antigens and sera showed different reactivity to the different antigens with the following percentages: 5%, 3%, 2%, 3% and 3% for L1 HPV-16, E6 HPV-16, E7 HPV-16, E6 HPV-18 and E7 HPV-18 respectively. [22] They had used GST capture ELISA for measuring anti-HPV antibodies, [22] unlike VLP L1 ELISA used in the present study. They concluded that Serology is not in itself a diagnostic method but must be kept in consideration for monitoring patients with an inflammatory cervical smear. Similarly, the determination of these antibodies by GST-capture ELISA and Luminex can help monitor vaccination programs on a large scale. [22] Yepinget al in 1999 evaluated the serological assays for HPV as screening tests for invasive cervical cancer . Serum samples were collected from 194 patients of cervical cancer. [23] HPV-16 VLP serology had a sensitivity of 47.4% and a specificity of 75.6%, whereas HPV-16 E6 and E7 serology had a sensitivity of 63.4% and a specificity of 89.9%. [23] Thus VLP ELISA detected only half of all the cases (Total n=194) of invasive cervical cancer. [23] The present study, however, had only 4 cases of invasive cervical cancer which did not show any detectable titre of antibodies.
Wideroff et al, however showed in their nested case control study of cervical intraepithelial neoplasia that overall, 30% of the patients with cervical intraepithelial neoplasia and 6.6% of the controls (without Cervical intraepithelial neoplasia) were positive for multiple types of HPV. [24] The discrepancy with our study can be explained by the following reasons:  Number of cases with CIN were 80 in the study done by Wideroff et al unlike 31 in the present study.  The above cited study included women of reproductive, perimenopausal and post-menopausal age group, unlike only perimenopausal women in the present study. And it is recorded that seroprevalence is more in women of reproductive age group. [7] This study was undertaken to determine the diagnostic accuracy of cervical cytology taking histopathology as the gold standard in perimenopausal women and to evaluate HPV VLP serology as a screening tool for cervical cancer, in addition to cervical cytology.Pap smear corroborated well with cervical histopathology. However, role of HPV VLP serology as a screening tool for cervical cancer could not be justified.
There can be two possible explanations for the above observation regarding HPV serology:
First, the sample size was much smaller than in similar studies.Secondly, it is well documented that serum anti-HPV antibody development requires a prolonged median lag period of ∼12 months from the first detection of HPV DNA, and the titer of detectable serum antibodies has been low (maximal, 1/200). [25] However, another fact of prime importance is that anti-VLP antibodies do not persist for years after infection. [7] In fact, sero-epidemiological data suggest that they disappear with age. [7] The age group included in the present study is that of women in the fifth decade, when any seroconversion which may have taken place several years back, wanes off. This may be a reason for obtaining no detectable titre of anti-HPV antibodies in majority of the cases.
